Rise in number of research activities focused towards developing efficient biomarkers can aid in early diagnosis of Alzheimer's and Parkinson's diseases growth

PORTLAND, OR, UNITED STATES, September 22, 2021 /EINPresswire.com/ -- Neurological Biomarkers Market for Alzheimer's and Parkinson's Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025. The report presents detailed analyses of the key market trends, drivers & opportunities, market size & forecasts, top investment pockets, and competitive landscape. According to the report, the neurological biomarkers market for Alzheimer's and Parkinson's disease was valued at $3.95 billion in 2017, and is expected to reach $8.57 billion by 2025, registering a CAGR of 10.1% from 2018 to 2025.

Introduction of affordable biomarker testing, growing demand for non-invasive diagnostic techniques, and increasing adoption in clinical trials drive the growth of the market. However, strict government regulations and ethical concerns regarding early diagnosis restrict the market growth. On the other hand, increased demand for personalized medicines would create new opportunities for the market.

Request for Sample Report for More Insights@ https://www.alliedmarketresearch.com/request-sample/3555

U.S. neurological Alzheimer's disease biomarkers market to contribute highest revenue by 2025:-

The neurological Alzheimer's disease biomarkers market in the U.S. contributed more than one-third of the global market revenue in in 2017, owing to significant increase in the number of educational institutes and rise in research & development activities. Asia-Pacific would grow at the fastest CAGR of 12.7% from 2018 to 2025, owing to rise in geriatric population who are suffer from Alzheimer's disease in countries such as India and Japan.

China neurological Parkinson's disease biomarkers market to grow the fastest through 2025:-

The neurological Parkinson's disease biomarkers market in China would grow at the fastest CAGR of 10.1% from 2018 to 2025 due to the rise in the number of individuals diagnosed with Parkinson's disease and implementation of pharmacological treatment and surgical intervention procedures. However, the U.S. contributed more than one-third of the total market share in 2017, owing to rise in prevalence of Parkinson's disease among geriatric population in the region.

Frontrunners in the industry:-

• The leading market players analyzed in the report include
• Abbott Laboratories,
• Proteome Sciences,
• Myriad RBM,
• Athena Diagnostics,
• Thermo Fisher Scientific,
• Quanterix Corporation,
• Immunarray Pvt. Ltd.,
• Psynova Neurotech,
• Diagenic ASA,
• Bio-Rad Laboratories.

These market players have adopted strategies such as partnerships, collaborations, expansions, joint ventures, and others to strengthen their position in the industry.

Inquiry For Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/3555

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.